StockData
Rein Therapeutics, Inc. logo

Rein Therapeutics, Inc. (RNTX) stock

RNTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$0.36−0.00 (-0.31%)

Close on Nov 18, 2026Market cap $30.65MP/E –Yield 0.00%

Rein Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Rein Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$49.46M. For fiscal 2025 it was -$50.63M. The highest annual figure on record is -$12.89M in fiscal 2015.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$50.63M–
FY2024Dec 31, 2024-$65.11M–
FY2023Dec 31, 2023-$16.28M–
FY2022Dec 31, 2022-$27.65M–
FY2021Dec 31, 2021-$26.61M–
FY2020Dec 31, 2020-$20.50M–
FY2019Dec 31, 2019-$29.96M–
FY2018Dec 31, 2018-$31.90M–
FY2017Dec 31, 2017-$23.01M–
FY2016Dec 31, 2016-$18.17M–
FY2015Dec 31, 2015-$12.89M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$6.08M–
Q1 FY2026Mar 31, 2026-$5.23M–
Q4 FY2025Dec 31, 2025-$32.66M–
Q3 FY2025Sep 30, 2025-$5.49M–
Q2 FY2025Jun 30, 2025-$6.87M–
Q1 FY2025Mar 31, 2025-$5.61M–
Q4 FY2024Dec 31, 2024-$42.80M–
Q3 FY2024Sep 30, 2024-$6.07M–
Q2 FY2024Jun 30, 2024-$9.04M–
Q1 FY2024Mar 31, 2024-$7.21M–
Q4 FY2023Dec 31, 2023-$7.29M–
Q3 FY2023Sep 30, 2023-$1.98M–
Q2 FY2023Jun 30, 2023-$1.99M–
Q1 FY2023Mar 31, 2023-$5.01M–
Q4 FY2022Dec 31, 2022-$4.70M–
Q3 FY2022Sep 30, 2022-$6.48M–
Q2 FY2022Jun 30, 2022-$8.04M–
Q1 FY2022Mar 31, 2022-$8.42M–
Q4 FY2021Dec 31, 2021-$6.82M–
Q3 FY2021Sep 30, 2021-$6.79M–
Q2 FY2021Jun 30, 2021-$6.01M–
Q1 FY2021Mar 31, 2021-$6.99M–
Q4 FY2020Dec 31, 2020-$4.19M–
Q3 FY2020Sep 30, 2020-$5.03M–
Q2 FY2020Jun 30, 2020-$4.40M–
Q1 FY2020Mar 31, 2020-$6.88M–
Q4 FY2019Dec 31, 2019-$7.35M–
Q3 FY2019Sep 30, 2019-$7.92M–
Q2 FY2019Jun 30, 2019-$7.38M–
Q1 FY2019Mar 31, 2019-$7.31M–
Q4 FY2018Dec 31, 2018-$6.98M–
Q3 FY2018Sep 30, 2018-$7.50M–
Q2 FY2018Jun 30, 2018-$9.66M–
Q1 FY2018Mar 31, 2018-$7.76M–
Q4 FY2017Dec 31, 2017-$7.04M–
Q3 FY2017Sep 30, 2017-$6.43M–
Q2 FY2017Jun 30, 2017-$4.95M–
Q1 FY2017Mar 31, 2017-$4.59M–
Q4 FY2016Dec 31, 2016-$4.45M–
Q3 FY2016Sep 30, 2016-$4.23M–

More Rein Therapeutics figures

See a number that looks wrong?